Connect with us

Hi, what are you looking for?

press release

Yaz Birth Control Case Ordered to Mediation, Explains Ennis & Ennis, P.A.

The Yaz Case that was Set for Trial is Going to Mediation per Judge’s Order

/EINPresswire.com/The first Yaz pulmonary embolism lawsuit that was scheduled to begin trial January 9, 2012 will not begin as planned. The Honorable David Herndon, who is the presiding judge on many Bayer birth control pill lawsuits, ordered the case to mediation. http://www.ilsd.uscourts.gov/Documents/mdl2100/Order53.pdf. “This is a good sign for both parties to begin the process of a global resolution to the litigation,” commented attorney Holly Ennis of Ennis & Ennis, P.A.

Currently there are thousands of lawsuits wherein women allege that Bayer failed to warn of increased risk of blood clots with birth control pills Yaz, Yasmin and Ocella. These lawsuits also allege that Bayer company officials wrongfully touted Yaz to be just a safe as other birth control pills and promoted the drug for uses not approved by the U.S. Food and Drug Administration (FDA). http://www.ilsd.uscourts.gov/mdl/mdl2100.aspx

A large number of these Yaz claims are filed in a federal multidistrict litigation (MDL) in the Southern District of Illinois wherein Judge Herndon hears all of the claims. This allows attorneys to gather necessary evidence for multiple cases simultaneously and avoids document duplications and inconsistent rulings. From these cases, one case in particular, Kerry Sims v. Bayer, was scheduled to begin trial, but will be mediated instead.

Judge Herndon appointed a Special Master, Stephen Saltzburg, a George Washington law professor, to mediate the Sims case. The Order states, “…the interests of this litigation, plaintiffs and defendants, will be better served by an alternative plan.”

Attorney Holly Ennis recommends that women who have taken Yaz or Yasmin and experienced blood clots, pulmonary embolisms, deep vein thrombosis, stroke or gallbladder disease should fill out a MedWatch Form at www.fda.gov and obtain the opinion of an experienced Yaz lawyer to explore their legal rights. Ennis & Ennis, P.A. has been investigating Yaz and Yasmin side effect cases since 2009.

Ennis & Ennis P.A. continues to offer free, nationwide, confidential consultations for women who have suffered Yaz and Yasmin side effects by calling toll free 1-800-856-6405 or by going to www.ennislaw.com and completing an online case evaluation form.

Ennis & Ennis, P.A. is a nationwide law firm with offices in Ft. Lauderdale, Miami and Washington D.C. that concentrates its practice in mass torts and represents individuals against pharmaceutical companies and medical device makers.

Ennis & Ennis, P.A. has been representing clients individually since 1986 and has recovered over $100 million in settlements for its clients.

Ennis & Ennis, P.A. is also investigating cases involving Accutane, Actos, Avandia, Fosamax, Plavix, Paxil, Zoloft, Prozac, Depuy Hip Recall, Zimmer Hip Recall, Wright Conserve Hips, Wright Profemur Hips, Depakote, Reglan, SJS/Dilantin, Transvaginal Mesh Devices, Yaz, Yasmin and Ocella Birth Control Pills.

Remember the law limits the time in which you can file a claim, so don’t wait. Call today toll free 1-800-856-6405 or visit www.ennislaw.com.

Ennis & Ennis, P.A. is a plaintiff’s national personal injury law firm that concentrates its practice on representing individuals who have been injured due to medication side effects, defective medical devices and defective products.

Media Contact:
Jami Angelini Haggerty
Ennis & Ennis, P.A.
(800) 856-6405
http://www.the-yaz-lawyer.com

PR courtesy of Online PR Media: http://bit.ly/xfoIng

You May Also Like

Business

State would join dozens of others in enacting legislation based on federal government’s landmark whistleblower statute, the False Claims Act

press release

With a deep understanding of the latest tech, Erbo helps businesses flourish in a digital world.

press release

#Automotive #Carbon #Canister #Market #Projected #Hit #USD New York, US, Oct. 24, 2022 (GLOBE NEWSWIRE) —  According to a comprehensive research report by Market...

press release

Barrington Research Analyst James C.Goss reiterated an Outperform rating on shares of IMAX Corp IMAX with a Price target of $20. As theaters...